# OnCo record paper-prophecy-arv7-validation-jco-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-prophecy-arv7-validation-jco-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-prophecy-arv7-validation-jco-2019" ;
  schema:name "PROPHECY: prospective multicentre validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer"@en ;
  schema:description "A blinded study across several hospitals confirmed that men whose circulating tumour cells carry the shortened androgen receptor live less long on hormone tablets, on two different tests that agree with each other four times in five."@en ;
  schema:url <https://onco.cc/key-papers/paper-prophecy-arv7-validation-jco-2019/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.18.01731>, <https://pubmed.ncbi.nlm.nih.gov/30865549/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.18.01731> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Armstrong AJ, Halabi S, Luo J, et al." ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/rna-splicing/>, <https://onco.cc/pathways/intravasation-ctc-survival/>, <https://onco.cc/pathways/resistance-routes-map/> ;
  onco:terms <https://onco.cc/terms/ar-v7/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/psa50/> ;
  onco:journals <https://onco.cc/journals/jco/> .